Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GID4 | Q8IVV7 | 2/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HHAT | Q5VTY9 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4616762 | 1.00 | GRIN2B (0.39) | GRIN2BKEAP1DRD3LMNAGID4 | |
| SCHEMBL3523506 | 0.80 | KEAP1 (0.33) | KEAP1DRD3NOS2 | |
| SCHEMBL3529213 | 0.80 | KEAP1 (0.33) | KEAP1DRD3NOS2 | |
| SCHEMBL3529215 | 0.80 | KEAP1 (0.33) | KEAP1DRD3NOS2 | |
| SCHEMBL6648853 | 0.77 | — | — | |
| SCHEMBL14916238 | 0.77 | — | — | |
| SCHEMBL14914794 | 0.77 | — | — | |
| SCHEMBL16519797 | 0.77 | GRIN2B (0.42) | GRIN2BKEAP1DRD3LMNAGID4 | |
| SCHEMBL6899248 | 0.77 | GRIN2B (0.39) | GRIN2BKEAP1DRD3LMNAGID4 | |
| SCHEMBL6101909 | 0.77 | KEAP1 (0.39) | GRIN2BKEAP1DRD3LMNAGID4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509950-B1 | 5-Amino-4-hydroxypentoyl amides | JANSSEN R & D IRELAND (IE) | 2015-02-25 | — | — | EP | disclosed |
| EP-2509950-B1 | 5-Amino-4-hydroxypentoyl amides | JANSSEN R & D IRELAND (IE) | 2015-02-25 | — | — | EP | disclosed |
| US-8592429-B2 | 5-amino-4-hydroxypentoyl amides | JANSSEN R&D IRELAND (IE) | 2013-11-26 | — | — | US | disclosed |
| US-20120295920-A1 | 5-AMINO-4-HYDROXYPENTOYL AMIDES | JANSSEN SCIENCES IRELAND UC (IE) | 2012-11-22 | — | — | US | disclosed |
| US-20120295920-A1 | 5-AMINO-4-HYDROXYPENTOYL AMIDES | JANSSEN SCIENCES IRELAND UC (IE) | 2012-11-22 | — | — | US | disclosed |
| US-20120295920-A1 | 5-AMINO-4-HYDROXYPENTOYL AMIDES | JANSSEN SCIENCES IRELAND UC (IE) | 2012-11-22 | — | — | US | disclosed |
| WO-2011070131-A1 | 5-AMINO- 4-HYDROXYPENTOYL AMIDES | TIBOTEC PHARMACEUTICALS (IE) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295920-A1 | 5-AMINO-4-HYDROXYPENTOYL AMIDES | C1S, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-10 | GRIN2B 4456/4885KEAP1 1942/4885DRD3 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.